-
Shortened Treatment Regimen Resolves C difficile Infection
12 May 2024 16:13 GMT
… Diseases, 3rd Faculty of Medicine, Charles University and … blinded, randomized placebo-controlled trial (RCT) with a … durations of vancomycin or fidaxomicin treatment, when compared to the … programs that promote appropriate antibiotic use.
The study…
-
Acurx Pharmaceuticals Announces Presentation of Ibezapolstat Phase 2 Clinical Trial Results at ESCMID Global 2024 Scientific Conference
03 May 2024 05:40 GMT
… to fidaxomicin and vancomycin … trials in accordance with the applicable FDA … trial performed as anticipated for both treatments, ibezapolstat and the control antibiotic … drug-resistant Streptococcus pneumoniae (DRSP).
To learn more about Acurx Pharmaceuticals …
-
Recursion Pharmaceuticals gets grant for pharmaceutical compounds for treating diseases
22 Apr 2024 13:20 GMT
… various stereoisomers, tautomers, and pharmaceutically acceptable salts. The patent also … therapeutic agents like vancomycin, fidaxomicin, or metronidazole.
The patent emphasizes … its applications in the treatment of specific medical conditions.
To know more …
-
What Is a Better Treatment Approach for Immunocompromised Hosts With Clostridioides difficile Infection?
22 Mar 2024 19:14 GMT
… trial data involve the use of vancomycin.3 Additionally, randomized controlled trials … including rates of concurrent antibiotics, community-acquired infection, … Efficacy and safety of fidaxomicin for the treatment of Clostridioides (Clostridium) …
-
Clostridium Difficile Infections Treatment Market is set to Reach US$ 1,727.1 million at a CAGR of 6.8% from the forecast period 2023 to 2031 | Growth Plus Reports
19 Feb 2024 06:13 GMT
…
Emergence of Antibiotic Resistance: Antibiotic resistance among … TREATMENT MARKET - ANALYSIS & FORECAST, BY DRUG
Metronidazole
Vancomycin
Fidaxomicin … the global medical clothing market was … EPhMRA (European Pharmaceutical Marketing Research Association …
-
New Healthcare-Associated Infection (HAI) Treatments Enhance Patient Care
15 Feb 2024 00:36 GMT
… and accessibility of alternative medications.
Main Takeaways
The introduction … microbiome-preserving antibiotic fidaxomicin, FMT, and FDA-approved microbiome-based treatments like … pathogenesis.
The Food and Drug Administration (FDA) has approved REBYOTA ( …
-
Acurx Pharmaceuticals, Inc. Reports Third Quarter 2023 Results and Provides Business Update
15 Nov 2023 10:38 GMT
… trial of ibezapolstat, its lead antibiotic candidate, for the treatment … trials. Preparation underway for End-of-Phase 2 FDA … difficile antibiotics fidaxomicin, vancomycin … drug-resistant Streptococcus pneumoniae (DRSP). To learn more about Acurx Pharmaceuticals …
-
What to know about antibiotic-associated diarrhea
21 Nov 2023 12:50 GMT
… underlying cause, treatment is different.
C.diff treatment
Treatment often requires … vein
antibiotics to treat the infection — usually vancomycin or fidaxomicin
… antibiotics when a doctor prescribes them
avoiding multiple antibiotics except when medically …
-
Acurx Pharmaceuticals, Inc. (NASDAQ:ACXP) Q3 2023 Earnings Call Transcript
15 Nov 2023 20:17 GMT
… 14, 2023
Acurx Pharmaceuticals, Inc. beats earnings … trial of ibezapolstat, our lead antibiotic candidate for the treatment … anti C. diff antibiotics, fidaxomicin, vancomycin and metronidazole, … Medicines Agency for conducting Phase III clinical trials …
-
Texas A&M Researchers Solve Mystery Behind Antibiotic-Resistant C. Difficile Infection
07 Nov 2023 20:17 GMT
… main two antibiotics used to treat C. diff infection, until fidaxomicin was … approved by the Food and Drug Administration in … already lost metronidazole as a treatment for C. diff and could …